Håkan mellstedt

Prof. Håkan mellstedt


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2018 in Leukemia
Verified
Journal Article
Open access
PDF file
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
ADA. H. Daneshmanesh
A. H. Daneshmanesh
AKA. S. Khan
A. S. Khan
JSJ. Shetye
J. Shetye
FMF. Mozaffari
F. Mozaffari
AMA. Moshfegh
A. Moshfegh

1 December 2013 in European Journal of Cancer Supplements
Verified
Journal Article
Open access
HMHåkan mellstedt
Håkan mellstedt
Biosimilar agents are approximate copies of branded biologic therapies. Since the first biosimilar was authorized in the European Union in 2006, fifteen additional agents have been approved by the European Medicines Agency, including two biosimilar monoclonal antibodies (mAbs). Biosimilar mAbs represent a distinct class given their large molecular size, complex protein structure, and post-translational modifications. While guidelines have been established for the development, approval, and use of biosimilars, further scrutiny and discussion is necessary to fully understand their potential impact on clinical outcomes. This review takes a critical look at the structural complexity of biosimilar mABs, the feasibility of indication extrapolation, the impact of product variability on immunogenicity, the importance of comprehensive pharmacovigilance, and the potential for ongoing pharmacoeconomic impact.

23 June 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
AGAmineh Ghaderi
Amineh Ghaderi
ADAmir Hossein Daneshmanesh
Amir Hossein Daneshmanesh
AMAli Moshfegh
Ali Moshfegh
PKParviz Kokhaei
Parviz Kokhaei
JVJan Vågberg
Jan Vågberg
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
The receptor tyrosine kinase ROR1 is absent in most normal adult tissues, but overexpressed in several malignancies. In this study, we explored clinical and functional inhibitory aspects of ROR1 in diffuse large B-cell lymphoma (DLBCL). ROR1 expression in tumor cells was more often observed in primary refractory DLBCL, Richter’s syndrome and transformed follicular lymphoma than in relapsed and non-relapsed DLBCL patients (p < 0.001). A survival effect of ROR1 expression was preliminarily observed in relapsed/refractory patients independent of gender and stage but not of age, cell of origin and international prognostic index. A second generation small molecule ROR1 inhibitor (KAN0441571C) induced apoptosis of ROR1+ DLBCL cell lines, similar to venetoclax (BCL-2 inhibitor) but superior to ibrutinib (BTK inhibitor). The combination of KAN0441571C and venetoclax at EC50 concentrations induced almost complete killing of DLBCL cell lines. Apoptosis was accompanied by the downregulation of BCL-2 and MCL-1 and confirmed by the cleavage of PARP and caspases 3, 8, 9. PI3Kδ/AKT/mTOR (non-canonical Wnt pathway) as well as β-catenin and CK1δ (canonical pathway) were inactivated. In zebra fishes transplanted with a ROR1+ DLBCL cell line, KAN0441571C induced a significant tumor reduction. New drugs with mechanisms of action other than those available for DLBCL are warranted. ROR1 inhibitors might represent a novel promising approach.

1 June 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ADAmir Hossein Daneshmanesh
Amir Hossein Daneshmanesh
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
AGAmineh Ghaderi
Amineh Ghaderi
AMAli Moshfegh
Ali Moshfegh
LHLotta Hansson
Lotta Hansson
HMHåkan mellstedt
Håkan mellstedt
There is a great unmet medical need in pancreatic carcinoma (PC) for novel drugs with other mechanisms of action than existing. PC cells express the onco-fetal RTK ROR1, absent on most normal post-partem cells. ROR1 is involved in proliferation, survival, EMT and metastasis of tumor cells in various malignancies. A small molecule inhibitor (KAN0439834) (530 Da) targeting the TK domain of ROR1 was developed and the activity in ROR1 expressing human PC cell lines (n = 8) evaluated. The effects were compared to a murine mAb against the external part of ROR1, gemcitabine, erlotinib and ibrutinib. KAN0439834 induced significant apoptosis of the tumor cells. EC50 values for KAN0439834 varied between 250–650 nM depending on the cell line. The corresponding values for erlotinib and ibrutinib were 10–40 folds higher. KAN0439834 was much more effective in inducing tumor cell death than the ROR1 mAb although both inhibited ROR1 phosphorylation and downstream non-canonical Wnt pathway molecules. Combination of KAN0439834 with erlotinib or ibrutinib had significant additive effects on tumor cell death. A first-in-class small molecule ROR1 inhibitor (KAN0439834) showed promising in vitro activity against a number of human PC cell lines. Interesting is the additive effects of erlotinib and ibrutinib which warrants further studies as both these agents are in clinical trials for pancreatic carcinoma.

1 July 2013 in Experimental Hematology
Verified
Journal Article
Closed access
MPMarzia Palma
Marzia Palma
APAnton Parker
Anton Parker
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
JFJade Forster
Jade Forster
PKParviz Kokhaei
Parviz Kokhaei
HMHåkan mellstedt
Håkan mellstedt

5 April 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
AGAmineh Ghaderi
Amineh Ghaderi
MOMohammad-Ali Okhovat
Mohammad-Ali Okhovat
JLJemina Lehto
Jemina Lehto
LPLuigi De Petris
Luigi De Petris
EDEhsan Manouchehri Doulabi
Ehsan Manouchehri Doulabi
Mohammad Hojjat-FarsangiMohammad Hojjat-Farsangi
Mohammad Hojjat-Farsangi
The ROR1 receptor tyrosine kinase is expressed in embryonic tissues but is absent in normal adult tissues. ROR1 is of importance in oncogenesis and is overexpressed in several cancers, such as NSCLC. In this study, we evaluated ROR1 expression in NSCLC patients (N = 287) and the cytotoxic effects of a small molecule ROR1 inhibitor (KAN0441571C) in NSCLC cell lines. ROR1 expression in tumor cells was more frequent in non-squamous (87%) than in squamous (57%) carcinomas patients, while 21% of neuroendocrine tumors expressed ROR1 (p = 0.0001). A significantly higher proportion of p53 negative patients in the ROR1+ group than in the p53 positive non-squamous NSCLC patients (p = 0.03) was noted. KAN0441571C dephosphorylated ROR1 and induced apoptosis (Annexin V/PI) in a time- and dose-dependent manner in five ROR1+ NSCLC cell lines and was superior compared to erlotinib (EGFR inhibitor). Apoptosis was confirmed by the downregulation of MCL-1 and BCL-2, as well as PARP and caspase 3 cleavage. The non-canonical Wnt pathway was involved. The combination of KAN0441571C and erlotinib showed a synergistic apoptotic effect. KAN0441571C also inhibited proliferative (cell cycle analyses, colony formation assay) and migratory (scratch wound healing assay) functions. Targeting NSCLC cells by a combination of ROR1 and EGFR inhibitors may represent a novel promising approach for the treatment of NSCLC patients.